At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
Tapinarof cream, 1%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-Label Maximal Use Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis
In Brief
A Phase 2 clinical trial evaluating Tapinarof cream, 1% for Plaque Psoriasis. Completed, enrolled 21 participants across 6 sites.
Detailed Summary
This is an open-label, multicenter study to evaluate the systemic exposure and safety of topical tapinarof cream, 1% under conditions of maximal use in adults with plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartJul 2019
First PostedAug 2019
Primary CompletionJan 2020
TodayJul 2026
First PostedAug 1, 2019
Enrollment StartJul 23, 2019
Primary CompletionJan 9, 2020
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 6.9 years ago
Interventions
Tapinarof cream, 1%drug
Tapinarof cream, 1% applied topically once daily